Alpa Laboratories enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


110	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
136	136	111	91.2	80.8
2.5	2.5	0.0	5.2	2.3
−23.3	—	—	—	—
−133	−133	−111	−86.0	−78.5
−₹11.09	—	—	—	—

189	189	171	157	137
1.3%	1.3%	0.0%	3.3%	1.7%
−0.11×	—	—	—	—

−0.21×	—	—	—	—
21.39×	—	—	—	—
6.96×	—	—	—	—
−3.89×	—	—	—	—
111	106	112	109	92.4
−1.1	3.3	4.8	8.1	7.6
−3.3	1.2	2.6	6.2	6.2
—	10.0	7.1	3.6	−4.8
6.0	6.0	−4.3	−2.7	−6.0
—	6.0	−4.4	−2.8	−6.0
—	4.0	11.4	6.4	1.1

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ALPA₹52.20

Alpa Laboratories Limited

· Pharma & Health

₹ CrorePeersBALPHARMA KREBSBIO NATCAPSUQ VINEETLAB NECLIFE AAREYDRUGS BIOFILCHEM MANGALAMMcap ₹110 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	109.8
- Cash, Equiv & ST Investments	80.8	91.2	110.5	135.7	135.7
+ Total Debt	2.3	5.2	0.0	2.5	2.5
Enterprise Value	—	—	—	—	-23.3
Net Debt (memo)	-78.5	-86.0	-110.5	-133.2	-133.2
EV per Share	—	—	—	—	-11.09

Total Capital	136.9	157.2	171.4	188.8	188.8
Total Debt/Total Capital	1.68	3.34	0.00	1.33	1.33
Total Debt/EV	—	—	—	—	-0.11

EV/Sales	—	—	—	—	-0.21
EV/EBITDA	—	—	—	—	21.39
EV/EBIT	—	—	—	—	6.96
EV/Free Cash Flow	—	—	—	—	-3.89
Reference Items — Trailing FY Values
Sales	92.4	108.7	112.5	105.8	110.6
EBITDA	7.6	8.1	4.8	3.3	-1.1
EBIT	6.2	6.2	2.6	1.2	-3.3
Operating Cash Flow	-4.8	3.6	7.1	10.0	—
Free Cash Flow	-6.0	-2.7	-4.3	6.0	6.0
FCFF (free cash flow to the firm)	-6.0	-2.8	-4.4	6.0	—
Capital Expenditure	1.1	6.4	11.4	4.0	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.